SEMA4A and neoplasm: Moreover, reprogrammed Tregs upregulate CD40L and are able to facilitate DC cross-presentation to activate CD8+ T-cell anti-tumor response after vaccination with an tumor antigen (91).The Nrp1-Sema4a pathway is another mechanism for reinforcing TIL Treg function and limiting anti-tumor immune responses, while it is dispensable for the suppression of autoimmunity and the maintenance of immune homeostasis by Tregs.